You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Regimens

95 Items
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    abiraterone - Metastatic castrate-resistant prostate cancer, according to specific criteria
ODB - General Benefit
    dexamethasone
Jun 2021
Cancer Type:
Breast, 
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Sep 2021
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Sep 2021
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
Apr 2021
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Palliative, Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    methotrexate - oral tablets
Exceptional Access Program
    tretinoin (ATRA)
Jul 2021
Cancer Type:
Central Nervous System
Intent: Palliative
Dec 2021
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Dec 2021
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Mar 2021
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Mar 2021
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Relapsed or Refractory Hodgkin Lymphoma
Nov 2021
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2021
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
ODB - General Benefit
    etoposide - oral capsules
Apr 2021

Pages